Manuscripts and Publications

Filters: First Letter Of Title is P  [Clear All Filters]
2021
Sales JM, Escoffery C, Hussen SA, Haddad LB, McCumber M, Kwiatkowski E, Filipowicz T, Sanchez M, Psioda MA, Sheth AN.  2021.  Pre-exposure Prophylaxis Implementation in Family Planning Services Across the Southern United States: Findings from a Survey Among Staff, Providers and Administrators Working in Title X-Funded Clinics.. AIDS Behav.
Coleman CG, Sales JM, Escoffery C, Piper KN, Powell L, Sheth AN.  2021.  Primary Care and Pre-exposure Prophylaxis Services in Publicly Funded Family Planning Clinics in the Southern United States.. J Gen Intern Med.
2020
Siegler AJ, C Mehta C, Mouhanna F, Giler RMera, Castel A, Pembleton E, Jaggi C, Jones J, Kramer MR, McGuinness P et al..  2020.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. Ann Epidemiol. 45:24-31.e3.
[Anonymous].  2020.  Precarious Work Involvement among Sexuality Minority and Transgender Youth of Color who are Unemployed or Underemployed in Chicago.
Siegler AJ.  2020.  Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision. Am J Public Health. 110(3):267-268.
Sheth AN, Hussen SA, Escoffery C, Haddad LB, Powell L, Brown N, Filipowicz TR, McCumber M, Sanchez M, Renshaw L et al..  2020.  Pre-Exposure Prophylaxis Integration Into Family Planning Services at Title X Clinics in the Southeastern United States: Protocol for a Mixed Methods Hybrid Type I Effectiveness Implementation Study (Phase 2 ATN 155). JMIR Res Protoc. 9(9):e18784.
[Anonymous].  2020.  Pre-Exposure Prophylaxis Integration into Family Planning Services at Title X Clinics in the Southeastern United States: A Mixed Methods Hybrid Type I Effectiveness Implementation Study—Phase 2 (ATN 155).
2019
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ.  2019.  Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
Biello KB, Psaros C, Krakower DS, Marrow E, Safren SA, Mimiaga MJ, Hightow-Weidman L, Sullivan P, Mayer KH.  2019.  A Pre-Exposure Prophylaxis Adherence Intervention (LifeSteps) for Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial.. JMIR Res Protoc. 8(1):e10661.
Sales JM, Escoffery C, Hussen SA, Haddad LB, Phillips A, Filipowicz T, Sanchez M, McCumber M, Rupp B, Kwiatkowski E et al..  2019.  Pre-Exposure Prophylaxis Integration into Family Planning Services at Title X Clinics in the Southeastern United States: A Geographically-Targeted Mixed Methods Study (Phase 1 ATN 155).. JMIR Res Protoc. 8(6):e12774.
Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME et al..  2019.  Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
2018
van den Berg JJ, Javanbakht M, Gorbach PM, Rudy BJ, Westfall AO, Wilson CM, Lally MA.  2018.  Partner Notification for Youth Living With HIV in 14 Cities in the United States.. J Acquir Immune Defic Syndr. 77(1):46-52.
Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, Gorbach P.  2018.  Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data.. AIDS Behav. 22(4):1174-1183.
Hosek SG, Harper GW, Lemos D, Burke-Miller J, Lee S, Friedman L, Martinez J.  2018.  Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV.. AIDS Behav. 22(8):2650-2661.
2016
Gross IMoses, Hosek S, Richards MHeather, M Fernández I.  2016.  Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
MacDonell KKolmodin, Jacques-Tiura AJ, Naar S, Fernandez MIsabella.  2016.  Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.. J Pediatr Psychol. 41(4):419-28.
Gamarel KE, Brown L, Kahler CW, M Fernández I, Bruce D, Nichols S.  2016.  Prevalence and correlates of substance use among youth living with HIV in clinical settings.. Drug Alcohol Depend. 169:11-18.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
2015
M Fernández I, Huszti HC, Wilson PA, Kahana S, Nichols S, Gonin R, Xu J, Kapogiannis BG.  2015.  Profiles of Risk Among HIV-Infected Youth in Clinic Settings.. AIDS Behav. 19(5):918-30.
Brown LK, Whiteley L, Harper GW, Nichols S, Nieves A.  2015.  Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
Hussen SA, Harper GW, Bauermeister JA, Hightow-Weidman LB.  2015.  Psychosocial influences on engagement in care among HIV-positive young black gay/bisexual and other men who have sex with men.. AIDS Patient Care STDS. 29(2):77-85.
2013
Ott MA, Alexander AB, Lally M, Steever JB, Zimet GD.  2013.  Preventive misconception and adolescents' knowledge about HIV vaccine trials.. J Med Ethics. 39(12):765-71.
Bangi A, M Dolcini M, Harper GW, Boyer CB, Pollack LM.  2013.  Psychosocial Outcomes of Sexual Risk Reduction in a Brief Intervention for Urban African American Female Adolescents.. J HIV AIDS Soc Serv. 12(2):146-159.
2012
Wilson EC, Iverson E, Garofalo R, Belzer M.  2012.  Parental support and condom use among transgender female youth.. J Assoc Nurses AIDS Care. 23(4):306-17.
Dempsey AG, Macdonell KE, Naar-King S, Lau C-Y.  2012.  Patterns of disclosure among youth who are HIV-positive: a multisite study.. J Adolesc Health. 50(3):315-7.
Doll M, Harper GW, Robles-Schrader GM, Johnson J, Bangi AK, Velagaleti S.  2012.  Perspectives of community partners and researchers about factors impacting coalition functioning over time.. J Prev Interv Community. 40(2):87-102.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Aaron KJ, Kempf M-C, Christenson RH, Wilson CM, Muntner P, Shrestha S.  2012.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
Reed SJ, Miller RLin, Francisco VT.  2012.  Programmatic capacity and HIV structural change interventions: influences on coalitions' success and efficiency in accomplishing intermediate outcomes.. J Prev Interv Community. 40(2):118-30.
2011
Baheti G, Kiser JJ, Havens PL, Fletcher CV.  2011.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
2010
Outlaw AY, Naar-King S, Janisse H, Parsons JT.  2010.  Predictors of condom use in a multisite study of high-risk youth living with HIV.. AIDS Educ Prev. 22(1):1-14.
Macdonell KE, Naar-King S, Murphy DA, Parsons JT, Harper GW.  2010.  Predictors of medication adherence in high risk youth of color living with HIV.. J Pediatr Psychol. 35(6):593-601.
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2010.  Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.. AIDS Patient Care STDS. 24(2):97-104.
M Dolcini M, Harper GW, Boyer CB, Pollack LM.  2010.  Project ORE: A friendship-based intervention to prevent HIV/STI in urban African American adolescent females.. Health Educ Behav. 37(1):115-32.
Naar-King S, Kolmodin K, Parsons JT, Murphy D.  2010.  Psychosocial factors and substance use in high-risk youth living with HIV: a multi-site study.. AIDS Care. 22(4):475-82.
2009
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2009.  Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.. AIDS Patient Care STDS. 23(3):185-94.
2008
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Warren JC, M Fernández I, Harper GW, Hidalgo MA, Jamil OB, Torres RSebastián.  2008.  Predictors of unprotected sex among young sexually active African American, Hispanic, and White MSM: the importance of ethnicity and culture.. AIDS Behav. 12(3):459-68.
2007
Straub DM, Deeds BGriffin, Willard N, Castor J, Peralta L, Francisco VT, Ellen J.  2007.  Partnership selection and formation: a case study of developing adolescent health community-researcher partnerships in fifteen U.S. communities.. J Adolesc Health. 40(6):489-98.
2006
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.